* TFF Pharmaceuticals Inc is expected to show a fall in quarterly revenue when it reports results on November 12 (estimated) for the period ending September 30 2024
* The Austin Texas-based company is expected to report a 14.9% decrease in revenue to $200 thousand from $235 thousand a year ago, according to the estimate from one analyst, based on LSEG data.
* LSEG's mean analyst estimate for TFF Pharmaceuticals Inc is for a loss of 81 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for TFF Pharmaceuticals Inc is $30.00, above its last closing price of $1.68.
This summary was machine generated November 8 at 23:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments